Repligen Co. (NASDAQ:RGEN) Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D boosted its position in shares of Repligen Co. (NASDAQ:RGEN) by 2.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,700 shares of the biotechnology company’s stock after purchasing an additional 382 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Repligen were worth $2,932,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after buying an additional 21,719 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after purchasing an additional 425,061 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after buying an additional 71,274 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. UBS Group reduced their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $150.47 on Thursday. The business has a 50 day simple moving average of $141.59 and a 200 day simple moving average of $144.78. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market capitalization of $8.43 billion, a price-to-earnings ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.23 earnings per share. On average, equities research analysts anticipate that Repligen Co. will post 1.45 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.